Core Laboratories Inc. /DE/(CLB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,788 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CLB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Core Laboratories Inc. /DE/ (CLB), a Energy sector company. 13F Pro's AI-powered ranking engine scores CLB at 44.0/100 on a 32-signal composite quality model, placing it at rank #1,788 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (19.8) and revenue growth (28.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 49.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Core Laboratories Inc. /DE/ reports quarterly revenue of $121.8M, net income of $-789.0K, free cash flow of $517.0K. Top institutional holders of CLB by reported 13-F value include ARIEL INVESTMENTS,, BlackRock,, DISCIPLINED GROWTH INVESTORS /MN, based on the most recent SEC filings. CLB trades on the NYSE exchange and files with the SEC under CIK 1958086. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Core Laboratories Inc. /DE/ directly from SEC EDGAR. Core Laboratories Inc. /DE/'s 13F Pro composite quality score has ranged between 8 and 61 since 2024, currently 44.0 — a stable long-term trajectory across 44 quarterly and live scoring snapshots.
Revenue
Q1 2026
$121.8M
Net Income
Q1 2026
$-789.0K
Free Cash Flow
Q1 2026
$517.0K
D/E Ratio
Q1 2026
0.44
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+7.0% YoYNet Income
+61.4% YoYOperating Income
+41.0% YoYEPS (Diluted)
+57.1% YoYTotal Assets
+2.1% YoYTotal Debt
-26.9% YoYOp. Cash Flow
+125.9% YoY| Metric | FY 2024 | FY 2022 | FY 2020 |
|---|---|---|---|
| Revenue | $523.8M +7.0% | $489.7M | — |
| Net Income | $31.4M +61.4% | $19.5M | — |
| Operating Income | $58.6M +41.0% | $41.5M | — |
| EPS (Diluted) | $0.66 +57.1% | $0.42 | — |
| Total Assets | $590.4M +2.1% | $578.4M | — |
| Total Debt | $128.0M -26.9% | $175.0M | — |
| Operating Cash Flow | $56.4M +125.9% | $25.0M | — |
AI Insight: CLB Financial Trends
Core Labs shows consistent Q1 seasonality weakness and debt reduction progress, but Q1 2026 operating income collapsed to $2M — the lowest in the observed period.
• Total debt fell from $150M in Q2 2024 to $113M in Q4 2025, a $37M reduction over six quarters, before ticking back to $117M in Q1 2026.
• Equity steadily expanded from $240M in Q2 2024 to $271M in Q3 2025, reflecting modest but consistent book-value accumulation.
• Revenue declined to $122M in Q1 2026 from $138M in Q4 2025, continuing a recurring first-quarter seasonal dip seen in Q1 2025 ($124M).
• Operating income dropped sharply to $2M in Q1 2026 from $16M in Q4 2025, the weakest operating result across all eight reported quarters.
⚠ Operating cash flow fell to $4M in Q1 2026, the lowest in the series — monitor whether this recovers in Q2 2026 as it did last year.
⚠ Net income turned negative (-$1M) in Q1 2026; Q1 2025 also printed near zero, suggesting structural cost pressure in slow quarters.
⚠ Debt ticked up from $113M to $117M in Q1 2026, interrupting the prior six-quarter deleveraging trend — worth tracking for reversal.
AI Insight: CLB Ratio Trends
Q1 2026 marks a second consecutive year of severe first-quarter deterioration, with operating margin collapsing to 1.6% and ROIC to 2.0%.
• Operating margin fell from 15.6% in Q3 2025 to 1.6% in Q1 2026, mirroring the Q1 2025 trough of 3.6%.
• Net profit margin turned negative at -0.7% in Q1 2026, repeating the -0.1% loss seen in Q1 2025.
• Leverage has improved steadily: D/E declined from 0.62 in Q2 2024 to 0.42 in Q4 2025, though it ticked back to 0.44 in Q1 2026.
• ROIC peaked at 21.6% in Q3 2025 but plunged to 2.0% in Q1 2026, the lowest single-quarter reading in the dataset.
⚠ Q1 weakness is a recurring pattern; monitor whether Q2 2026 margins recover toward the 11–12% range seen in prior Q2s.
⚠ TTM NPM of 5.5% masks the Q1 2026 loss; sustained negative quarterly earnings could pressure the balance sheet.
⚠ D/E edged up to 0.44 in Q1 2026 after six quarters of decline — watch for leverage re-expansion if losses persist.
Get alerted when CLB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Core Laboratories Inc. /DE/ including:
Top Institutional Holders of CLB
ARIEL INVESTMENTS, LLC
$221.1M13,170,388 shBlackRock, Inc.
$121.0M7,208,503 shDISCIPLINED GROWTH INVESTORS INC /MN
$82.9M4,937,115 shEARNEST PARTNERS LLC
$51.3M3,055,996 shSTATE STREET CORP
$34.6M2,060,537 shCWA Asset Management Group, LLC
$29.2M1,741,001 shVANGUARD CAPITAL MANAGEMENT LLC
$27.2M1,619,863 shDIMENSIONAL FUND ADVISORS LP
$22.7M1,352,329 shVANGUARD PORTFOLIO MANAGEMENT LLC
$21.1M1,254,836 shGEODE CAPITAL MANAGEMENT, LLC
$19.1M1,137,958 sh
| Fund | Value | Shares |
|---|---|---|
| ARIEL INVESTMENTS, LLC | $221.1M | 13,170,388 |
| BlackRock, Inc. | $121.0M | 7,208,503 |
| DISCIPLINED GROWTH INVESTORS INC /MN | $82.9M | 4,937,115 |
| EARNEST PARTNERS LLC | $51.3M | 3,055,996 |
| STATE STREET CORP | $34.6M | 2,060,537 |
| CWA Asset Management Group, LLC | $29.2M | 1,741,001 |
| VANGUARD CAPITAL MANAGEMENT LLC | $27.2M | 1,619,863 |
| DIMENSIONAL FUND ADVISORS LP | $22.7M | 1,352,329 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $21.1M | 1,254,836 |
| GEODE CAPITAL MANAGEMENT, LLC | $19.1M | 1,137,958 |
More Energy Companies
View all Energy →Put CLB on your watchlist
Track score changes the day Core Laboratories Inc. /DE/ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CLB a good stock to buy?
13F Pro's AI-powered analysis of Core Laboratories Inc. /DE/ (CLB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Energy sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLB are available on the CLB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CLB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Core Laboratories Inc. /DE/'s investment landscape.